Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Jasper Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Jasper Therapeutics announced earnings per share of $-0.304 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.333 on revenue of $0.00.
Jasper Therapeutics 's are down 53.92% and is trading at $0.660 , still down 93.83% from its 52 week high of $10.69 set on Thursday, December 9, 2021.
Jasper Therapeutics follows other major Healthcare sector earnings this month
Jasper Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar